The M&A paradox: Why signing the deal is just the beginning
Why now
Thesis: Biotech M&A integration risk is the real test
Catalyst to watch: Announced deal closings and integration updates
Main risk: Integration failures could deter future deals
Why it matters
Duplicate biotech M&A integration commentary; execution risk after signing is the theme.
Sources
- googlenews · news.google.com · 2026-09-24 15:32 UTC